X

Sign up for Equitymaster's free daily newsletter, The 5 Minute WrapUp and get access to our latest Multibagger guide (2018 Edition) on picking money-making stocks.

This is an entirely free service. No payments are to be made.


Download Now Subscribe to our free daily e-letter, The 5 Minute WrapUp and get this complimentary report.
We hate spam as much as you do. Check out our Privacy Policy and Terms Of Use.
Compare Cipla with VENUS REMEDIES - Equitymaster

Helping You Build Wealth With Honest Research
Since 1996. Try Now

  • MyStocks

MEMBER'S LOGINX

     
Login Failure
   
     
   
     
 
 
 
(Please do not use this option on a public machine)
 
     
 
 
 
  Sign Up | Forgot Password?  

CIPLA vs VENUS REMEDIES - Comparison Results

CIPLA    Change

Cipla is one of the largest pharma companies in the domestic market and has presence in formulations and bulk drugs manufacturing. All the bulk drug manufacturing facilities of the company have been approved by various authorities including the US FD... More

DO YOU LIKE THESE REPORTS? TELL US!

Current Valuations

    CIPLA VENUS REMEDIES CIPLA/
VENUS REMEDIES
 
P/E (TTM) x 37.5 -9.0 - View Chart
P/BV x 3.9 0.1 2,757.6% View Chart
Dividend Yield % 0.3 0.0 -  

Financials

 CIPLA   VENUS REMEDIES
EQUITY SHARE DATA
    CIPLA
Mar-17
VENUS REMEDIES
Mar-17
CIPLA/
VENUS REMEDIES
5-Yr Chart
Click to enlarge
High Rs622143 435.5%   
Low Rs45865 705.1%   
Sales per share (Unadj.) Rs181.9324.2 56.1%  
Earnings per share (Unadj.) Rs12.96.4 200.8%  
Cash flow per share (Unadj.) Rs29.340.6 72.2%  
Dividends per share (Unadj.) Rs2.000-  
Dividend yield (eoy) %0.40-  
Book value per share (Unadj.) Rs155.7366.0 42.5%  
Shares outstanding (eoy) m804.5112.34 6,519.5%   
Bonus/Rights/Conversions ESOP--  
Price / Sales ratio x3.00.3 926.7%   
Avg P/E ratio x42.016.2 258.9%  
P/CF ratio (eoy) x18.42.6 719.5%  
Price / Book Value ratio x3.50.3 1,221.9%  
Dividend payout %15.50-   
Avg Mkt Cap Rs m434,5161,282 33,890.3%   
No. of employees `00023.00.9 2,551.8%   
Total wages/salary Rs m26,338251 10,493.3%   
Avg. sales/employee Rs Th6,349.14,430.1 143.3%   
Avg. wages/employee Rs Th1,143.0278.0 411.2%   
Avg. net profit/employee Rs Th449.387.6 513.0%   
INCOME DATA
Net Sales Rs m146,3024,000 3,657.2%  
Other income Rs m2,28723 10,074.4%   
Total revenues Rs m148,5894,023 3,693.4%   
Gross profit Rs m24,758785 3,155.1%  
Depreciation Rs m13,229422 3,137.9%   
Interest Rs m1,594344 463.7%   
Profit before tax Rs m12,22242 29,030.2%   
Minority Interest Rs m00-   
Prior Period Items Rs m-700-   
Extraordinary Inc (Exp) Rs m00-   
Tax Rs m1,798-37 -4,858.4%   
Profit after tax Rs m10,35479 13,090.0%  
Gross profit margin %16.919.6 86.3%  
Effective tax rate %14.7-87.9 -16.7%   
Net profit margin %7.12.0 357.9%  
BALANCE SHEET DATA
Current assets Rs m87,3702,606 3,352.4%   
Current liabilities Rs m33,0811,980 1,670.5%   
Net working cap to sales %37.115.6 237.2%  
Current ratio x2.61.3 200.7%  
Inventory Days Days87128 67.8%  
Debtors Days Days6243 144.4%  
Net fixed assets Rs m111,5675,353 2,084.1%   
Share capital Rs m1,609123 1,303.9%   
"Free" reserves Rs m123,6454,393 2,814.9%   
Net worth Rs m125,2544,516 2,773.6%   
Long term debt Rs m36,4541,618 2,252.7%   
Total assets Rs m209,5328,291 2,527.2%  
Interest coverage x8.71.1 772.2%   
Debt to equity ratio x0.30.4 81.2%  
Sales to assets ratio x0.70.5 144.7%   
Return on assets %5.75.1 111.8%  
Return on equity %8.31.8 472.0%  
Return on capital %8.56.3 135.2%  
Exports to sales %34.20-   
Imports to sales %8.318.4 45.3%   
Exports (fob) Rs m50,050NA-   
Imports (cif) Rs m12,203736 1,657.3%   
Fx inflow Rs m51,0660-   
Fx outflow Rs m17,678736 2,400.9%   
Net fx Rs m33,388-736 -4,534.6%   
CASH FLOW
From Operations Rs m23,824997 2,389.1%  
From Investments Rs m-13,127-461 2,845.5%  
From Financial Activity Rs m-13,239-571 2,318.5%  
Net Cashflow Rs m-2,478-35 7,059.8%  

Share Holding

Indian Promoters % 16.0 32.9 48.7%  
Foreign collaborators % 20.8 0.0 -  
Indian inst/Mut Fund % 12.2 0.2 6,777.8%  
FIIs % 23.7 0.6 4,086.2%  
ADR/GDR % 1.1 0.0 -  
Free float % 26.2 66.4 39.5%  
Shareholders   161,166 20,121 801.0%  
Pledged promoter(s) holding % 0.0 36.4 -  
NM: Not Meaningful
Source: Company Annual Reports, Regulatory Filings, Equitymaster

Compare CIPLA With:   SUVEN LIFE  ORCHID PHARMA LTD  NOVARTIS  TTK HEALTHCARE  SHASUN PHARMA  

Compare CIPLA With:   ACTAVIS (US)  ADCOCK INGRAM (S. Africa)  MYLAN (US)  TEVA PHARMA (Israel)  



Today's Market

Sensex Ends Volatile Day in Red; Pharma Stocks Lose Most(Closing)

After opening the day in green, share markets in India witnessed volatile trading activity throughout the day and ended the day on a negative note.

Related Views on News

VENUS REMEDIES Announces Quarterly Results (4QFY18); Net Profit Down 307.2%

Jun 12, 2018 | Updated on Jun 12, 2018

For the quarter ended March 2018, VENUS REMEDIES has posted a net profit of Rs 94 m (down 307.2% YoY). Sales on the other hand came in at Rs 932 m (up 16.8% YoY). Read on for a complete analysis of VENUS REMEDIES's quarterly results.

CIPLA Announces Quarterly Results (4QFY18); Net Profit Down 347.8%

May 24, 2018 | Updated on May 24, 2018

For the quarter ended March 2018, CIPLA has posted a net profit of Rs 2 bn (down 347.8% YoY). Sales on the other hand came in at Rs 37 bn (up 3.2% YoY). Read on for a complete analysis of CIPLA's quarterly results.

Aster DM Healthcare (IPO)

Feb 10, 2018

Should you subscribe to the IPO of Aster DM Healthcare Ltd?

Dr Reddy's: Milestone Payment Drives Sales (Quarterly Results Update - Detailed)

Feb 9, 2018

US business was hit by pricing pressure although there was growth sequentially led by new product launches.

Lupin: US market Declines Due to Higher Base Effect of FY17 (Quarterly Results Update - Detailed)

Feb 9, 2018

Price erosion in generic US drugs continues but seems to be bottoming out.

More Views on News

Most Popular

After Vakrangee and Manpasand, More Auditors May Soon Resign. To Protect Your Wealth, Avoid these Stocks(The 5 Minute Wrapup)

Jun 8, 2018

The change in auditing regulations can bring a big change in corporate governance behaviour in the mid and small-cap space.

Alert: Pharma Stocks Are About to Shoot Up - And a Superb Stock for Trading(Profit Hunter)

Jun 13, 2018

The ailing pharma stocks are bouncing back to health. Read this to find out the best way to profit from them.

GST Will Not Solve Problem of High Prices of Petrol and Diesel(Vivek Kaul's Diary)

Jun 13, 2018

Though it will bring transparency in their pricing and that in itself will be a welcome move.

Has the Market Bottomed Out?(Sector Info)

Jun 11, 2018

The yield spread is an effective barometer that can indicate the direction the markets are headed.

Is Data Pointing Towards a Revival in the FMCG Sector?(Sector Info)

Jun 8, 2018

After several quarters of stress in the aftermath of demonetisation and the rollout of GST, this data is pointing towards revival in the India's rural FMCG industry.

More

Small Investments
BIG Returns

Zero To Millions Guide 2018
Get our special report, Zero To Millions
(2018 Edition) Now!
We will never sell or rent your email id.
Please read our Terms

CIPLA SHARE PRICE


Jun 21, 2018 (Close)

TRACK CIPLA

COMPARE CIPLA WITH

MARKET STATS